Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 329

1.

GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses.

Lo MK, Jordan R, Arvey A, Sudhamsu J, Shrivastava-Ranjan P, Hotard AL, Flint M, McMullan LK, Siegel D, Clarke MO, Mackman RL, Hui HC, Perron M, Ray AS, Cihlar T, Nichol ST, Spiropoulou CF.

Sci Rep. 2017 Mar 6;7:43395. doi: 10.1038/srep43395.

2.

Bayesian Model Assessment in Joint Modeling of Longitudinal and Survival Data with Applications to Cancer Clinical Trials.

Zhang D, Chen MH, Ibrahim JG, Boye ME, Shen W.

J Comput Graph Stat. 2017;26(1):121-133. doi: 10.1080/10618600.2015.1117472. Epub 2017 Feb 16.

3.

Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome.

Abram ME, Ram RR, Margot NA, Barnes TL, White KL, Callebaut C, Miller MD.

PLoS One. 2017 Feb 17;12(2):e0172206. doi: 10.1371/journal.pone.0172206. eCollection 2017 Feb 17.

4.

Cropping system diversification for food production in Mindanao rubber plantations: a rice cultivar mixture and rice intercropped with mungbean.

Hondrade RF, Hondrade E, Zheng L, Elazegui F, Duque JL, Mundt CC, Vera Cruz CM, Garrett KA.

PeerJ. 2017 Feb 8;5:e2975. doi: 10.7717/peerj.2975. eCollection 2017 Feb 8.

5.

Viability of primary osteoblasts after treatment with tenofovir alafenamide: Lack of cytotoxicity at clinically relevant drug concentrations.

Callebaut C, Liu Y, Babusis D, Ray A, Miller M, Kitrinos K.

PLoS One. 2017 Feb 9;12(2):e0169948. doi: 10.1371/journal.pone.0169948. eCollection 2017 Feb 9.

6.

PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors.

Yahiaoui A, Meadows SA, Sorensen RA, Cui ZH, Keegan KS, Brockett R, Chen G, Quéva C, Li L, Tannheimer SL.

PLoS One. 2017 Feb 8;12(2):e0171221. doi: 10.1371/journal.pone.0171221. eCollection 2017 Feb 8.

7.

The Smc5/6 Complex Restricts HBV when Localized to ND10 without Inducing an Innate Immune Response and Is Counteracted by the HBV X Protein Shortly after Infection.

Niu C, Livingston CM, Li L, Beran RK, Daffis S, Ramakrishnan D, Burdette D, Peiser L, Salas E, Ramos H, Yu M, Cheng G, Strubin M, Delaney Iv WE, Fletcher SP.

PLoS One. 2017 Jan 17;12(1):e0169648. doi: 10.1371/journal.pone.0169648. eCollection 2017 Jan 17.

8.

Targeting LOXL2 for cardiac interstitial fibrosis and heart failure treatment.

Yang J, Savvatis K, Kang JS, Fan P, Zhong H, Schwartz K, Barry V, Mikels-Vigdal A, Karpinski S, Kornyeyev D, Adamkewicz J, Feng X, Zhou Q, Shang C, Kumar P, Phan D, Kasner M, López B, Diez J, Wright KC, Kovacs RL, Chen PS, Quertermous T, Smith V, Yao L, Tschöpe C, Chang CP.

Nat Commun. 2016 Dec 14;7:13710. doi: 10.1038/ncomms13710.

9.

Use of a cocktail probe to assess potential drug interactions with cytochrome P450 after administration of belatacept, a costimulatory immunomodulator.

Williams D, Tao X, Zhu L, Stonier M, Lutz JD, Masson E, Zhang S, Ganguly B, Tzogas Z, Lubin S, Murthy B.

Br J Clin Pharmacol. 2017 Feb;83(2):370-380. doi: 10.1111/bcp.13097. Epub 2016 Nov 2.

10.

Role of Mitochondrial Toxicity in BMS-986094-Induced Toxicity.

Feng JY, Tay CH, Ray AS.

Toxicol Sci. 2017 Jan;155(1):2. doi: 10.1093/toxsci/kfw224. Epub 2016 Nov 1. No abstract available.

11.

TLR7 Agonist GS-9620 Is a Potent Inhibitor of Acute HIV-1 Infection in Human Peripheral Blood Mononuclear Cells.

Bam RA, Hansen D, Irrinki A, Mulato A, Jones GS, Hesselgesser J, Frey CR, Cihlar T, Yant SR.

Antimicrob Agents Chemother. 2016 Dec 27;61(1). pii: e01369-16. doi: 10.1128/AAC.01369-16. Print 2017 Jan.

12.

Pharmacokinetics, Pharmacodynamics, and Safety of Entospletinib, a Novel pSYK Inhibitor, Following Single and Multiple Oral Dosing in Healthy Volunteers.

Ramanathan S, Di Paolo JA, Jin F, Shao L, Sharma S, Robeson M, Kearney BP.

Clin Drug Investig. 2017 Feb;37(2):195-205. doi: 10.1007/s40261-016-0476-x.

13.

Correlates of disease-specific knowledge among patients with chronic hepatitis B or hepatitis C infection in India.

Tamayo A, Shah SR, Bhatia S, Chowdhury A, Rao PN, Dinh P, Knox SJ, Gaggar A, Subramanian GM, Mohan VG, Sood A, Mehta R, Sarin SK.

Hepatol Int. 2016 Nov;10(6):988-995. Epub 2016 May 4.

14.

A Randomized, Open-Label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Darunavir in Treatment-Experienced HIV-1-Infected Adults.

Huhn GD, Tebas P, Gallant J, Wilkin T, Cheng A, Yan M, Zhong L, Callebaut C, Custodio JM, Fordyce MW, Das M, McCallister S.

J Acquir Immune Defic Syndr. 2017 Feb 1;74(2):193-200. doi: 10.1097/QAI.0000000000001193.

15.

Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide.

Funderburg NT, McComsey GA, Kulkarni M, Bannerman T, Mantini J, Thornton B, Liu HC, Zhang Y, Song Q, Fang L, Dinoso J, Cheng A, McCallister S, Fordyce MW, Das M.

EBioMedicine. 2016 Nov;13:321-327. doi: 10.1016/j.ebiom.2016.10.009. Epub 2016 Oct 11.

16.

Primary care clinicians' experiences prescribing HIV pre-exposure prophylaxis at a specialized community health centre in Boston: lessons from early adopters.

Krakower DS, Maloney KM, Grasso C, Melbourne K, Mayer KH.

J Int AIDS Soc. 2016 Oct 11;19(1):21165. doi: 10.7448/IAS.19.1.21165. eCollection 2016 Oct 11. Erratum in: J Int AIDS Soc. 2016 Oct 28;19(1):21596.

17.

Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in Asian Subjects with Human Immunodeficiency Virus 1 Infection: A Sub-Analysis of Phase 3 Clinical Trials.

Choi JY, Sungkanuparph S, Anekthananon T, Sax P, DeJesus E, Edelstein H, Nelson M, DeMorin J, Liu HC, Swamy R, Bahn J, Hwang S, Yang SY, Ng C, Piontkowsky D.

Infect Chemother. 2016 Sep;48(3):219-224. doi: 10.3947/ic.2016.48.3.219.

18.

Early somatic mosaicism is a rare cause of long-QT syndrome.

Priest JR, Gawad C, Kahlig KM, Yu JK, O'Hara T, Boyle PM, Rajamani S, Clark MJ, Garcia ST, Ceresnak S, Harris J, Boyle S, Dewey FE, Malloy-Walton L, Dunn K, Grove M, Perez MV, Neff NF, Chen R, Maeda K, Dubin A, Belardinelli L, West J, Antolik C, Macaya D, Quertermous T, Trayanova NA, Quake SR, Ashley EA.

Proc Natl Acad Sci U S A. 2016 Oct 11;113(41):11555-11560. Epub 2016 Sep 28.

19.

DNA-linked Inhibitor Antibody Assay (DIANA) for sensitive and selective enzyme detection and inhibitor screening.

Navrátil V, Schimer J, Tykvart J, Knedlík T, Vik V, Majer P, Konvalinka J, Šácha P.

Nucleic Acids Res. 2017 Jan 25;45(2):e10. doi: 10.1093/nar/gkw853. Epub 2016 Sep 26.

20.

Brief Report: Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Adults With Renal Impairment: 96-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study.

Post FA, Tebas P, Clarke A, Cotte L, Short WR, Abram ME, Jiang S, Cheng A, Das M, Fordyce MW.

J Acquir Immune Defic Syndr. 2017 Feb 1;74(2):180-184. doi: 10.1097/QAI.0000000000001186.

Supplemental Content

Loading ...
Support Center